Compare LAES & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LAES | ALLO |
|---|---|---|
| Founded | 2022 | 2017 |
| Country | Switzerland | United States |
| Employees | N/A | 152 |
| Industry | Semiconductors | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 675.0M | 722.1M |
| IPO Year | 2022 | 2018 |
| Metric | LAES | ALLO |
|---|---|---|
| Price | $2.54 | $2.10 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 15 |
| Target Price | $4.00 | ★ $8.35 |
| AVG Volume (30 Days) | ★ 12.7M | 5.9M |
| Earning Date | 03-31-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 34.09 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $93.36 | N/A |
| Revenue Next Year | $43.06 | $142,416.42 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.99 | $1.04 |
| 52 Week High | $8.71 | $4.46 |
| Indicator | LAES | ALLO |
|---|---|---|
| Relative Strength Index (RSI) | 46.16 | 54.73 |
| Support Level | $2.28 | $2.07 |
| Resistance Level | $2.65 | $2.25 |
| Average True Range (ATR) | 0.15 | 0.11 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 26.25 | 65.85 |
SEALSQ Corp develops certified secure microcontrollers and implements post-quantum cryptography. The company develops solutions including post-quantum microchips and devices that can be used in a variety of applications, from multi-factor authentication, home automation, and IT network infrastructure to automotive, industrial automation, and control systems. The company's vaultIC range offers a set of ready-to-use secure elements designed to implement embedded security for any kind of device with fast time-to-market and high flexibility. The company's products include VaultIC155, VaultIV18x, VaultIC292, and VaultIC40x. The company generates a majority of its revenue from North America, while it also has its presence in Europe, Middle East & Africa, Asia Pacific, and Latin America.
Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf" T cell candidates designed to target cancer cells or eliminate autoreactive cells in patients with autoimmune disorders. Its three core programs are: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID) and Renal Cell Carcinoma (RCC).